Literature DB >> 29305812

Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?

Nazzareno Cervelli1,2, Giuliano Tocci3,2,4, Claudio Ferri5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29305812     DOI： 10.1007/s40292-017-0244-x

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN： 1120-9879


× No keyword cloud information.
  17 in total

Review 1.  Emerging biologic therapies for hypercholesterolaemia.

Authors:  Giacomo Pucci; Arrigo F Cicero; Claudio Borghi; Giuseppe Schillaci
Journal:  Expert Opin Biol Ther       Date:  2017-06-15       Impact factor: 4.388

2.  Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs.

Authors:  Salim S Virani; Julia M Akeroyd; Vijay Nambi; Paul A Heidenreich; Pamela B Morris; Khurram Nasir; Erin D Michos; Vera A Bittner; Laura A Petersen; Christie M Ballantyne
Journal:  Circulation       Date:  2017-05-02       Impact factor: 29.690

3.  Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).

Authors:  Marc P Bonaca; Patrice Nault; Robert P Giugliano; Anthony C Keech; Armando Lira Pineda; Estella Kanevsky; Julia Kuder; Sabina A Murphy; J Wouter Jukema; Basil S Lewis; Lale Tokgozoglu; Ransi Somaratne; Peter S Sever; Terje R Pedersen; Marc S Sabatine
Journal:  Circulation       Date:  2017-11-13       Impact factor: 29.690

4.  Neurocognitive performance after PCSK9 inhibitor therapy: Current state of the evidence.

Authors:  Cosimo Andrea Stamerra; Paolo Di Giosia; Paolo Giorgini; Martina De Feo; Davide Grassi; Claudio Ferri; Amirhossein Sahebkar
Journal:  J Neurosci Res       Date:  2017-11-20       Impact factor: 4.164

Review 5.  2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document.

Authors:  Massimo Volpe; Roberto Volpe; Giovanna Gallo; Vivianne Presta; Giuliano Tocci; Emanuela Folco; Andrea Peracino; Elena Tremoli; Bruno Trimarco
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-05-18

6.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.

Authors:  Paul S Jellinger; Yehuda Handelsman; Paul D Rosenblit; Zachary T Bloomgarden; Vivian A Fonseca; Alan J Garber; George Grunberger; Chris K Guerin; David S H Bell; Jeffrey I Mechanick; Rachel Pessah-Pollack; Kathleen Wyne; Donald Smith; Eliot A Brinton; Sergio Fazio; Michael Davidson
Journal:  Endocr Pract       Date:  2017-04       Impact factor: 3.443

7.  Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.

Authors:  Robert P Giugliano; Terje R Pedersen; Jeong-Gun Park; Gaetano M De Ferrari; Zbigniew A Gaciong; Richard Ceska; Kalman Toth; Ioanna Gouni-Berthold; Jose Lopez-Miranda; François Schiele; François Mach; Brian R Ott; Estella Kanevsky; Armando Lira Pineda; Ransi Somaratne; Scott M Wasserman; Anthony C Keech; Peter S Sever; Marc S Sabatine
Journal:  Lancet       Date:  2017-08-28       Impact factor: 79.321

Review 8.  Hyperlipidemia as a risk factor for cardiovascular disease.

Authors:  Robert H Nelson
Journal:  Prim Care       Date:  2012-12-04       Impact factor: 2.907

9.  Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE)

Authors:  F M Sacks; M A Pfeffer; L Moye'; L E Brown; P Hamm; T G Cole; C M Hawkins; E Braunwald
Journal:  Am J Cardiol       Date:  1991-12-01       Impact factor: 2.778

Review 10.  Retargeting the management of hypercholesterolemia - focus on evolocumab.

Authors:  Alessandro Colletti; Giuseppe Derosa; Arrigo Fg Cicero
Journal:  Ther Clin Risk Manag       Date:  2016-09-06       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.